Stock Watch: Lilly And Novo Provide An Earnings Season Crescendo
Second Quarter Results Had Been Mixed
The commercial and clinical successes of Lilly and Novo's respective GLP-1 receptor agonists provided an explosive finale to the second-quarter earnings season but also raised questions on reimbursement.
